1. Pink Sheet
  2. >>Market Access

Mark Cuban: Pharma’s Secret Weapon In The Fight Against PBMs

 
• By Sarah Karlin-Smith

The well-known businessman and TV personality told the White House that the US needs to ‘stop doing business with the big three PBMs,’ helping to fight the drug industry’s battle against the middlemen with a friendlier face not associated directly with the brand industry.

Mark Cuban at White House on 4 March 2024
Mark Cuban was part of a White House panel on PBM issues that did not include any PBMs. • Source: Screenshot of White House feed

The pharmaceutical industry wasn’t directly represented at the White House’s pharmacy benefits management roundtable on 4 March, but their agenda – to put the onus of drug affordability challenges on PBMs – took center stage, offered by actors who likely make the industry’s messages more palatable.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from PBMs

PBMs Must Prepare For Revival Of Drug Price Transparency Requirements

 
• By Jill Drachenberg

Experts say PBMs should become familiar with transparency rules and prepare to release data, although more legal wrangling could occur.

Is Optum Rx Payment Remodel To Favor Generics A Peace Offering For US FTC?

 
• By Urtė Fultinavičiūtė

Optum Rx, one of the largest PBMs in the US, declared it was the “first comprehensive, transparent pharmacy services company” after announcing several consumer-friendly changes.

Study Shows ‘Insurer-PBMs’ Dominate Medicare Part D, Steer Patients to Their Pharmacies

 
• By Jinghong Chen

An analysis of Medicare Part D and other data found that more than one-third of all pharmacy spending went through pharmacies owned by Cigna, CVS Health, Humana or UnitedHealth Group.

PBM Reform Legislation Do-Over Will Need Bipartisan Help Amid Partisan Budget Battle

 
• By Cathy Kelly

The leader of the House Energy and Commerce Health Subcommittee has a plan for passing pharmacy benefit manager reforms, but Democrats are skeptical.

More from Market Access

Leqembi Launch Set For Germany & Austria After Winning EU Approval At Last

 
• By Neena Brizmohun

Eisai is working on securing reimbursement across the EU for Leqembi now that the Alzheimer’s disease treatment has secured marketing approval from the European Commission.

African Medicines Agency Set To Launch With New Leader In April

 
• By Anabel Costa-Ferreira

The African Medicines Agency is to appoint a director general and become operational at the end of this month.

EU Regulators Push For Better Support For Sponsors On Using Animal Study Alternatives

 
• By Eliza Slawther

The European Medicines Agency’s innovation network has recommended how the EU’s regulatory framework could be updated to support drug developers in using new approach methodologies, which are drug testing methods that reduce or replace animal studies.